The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Status:
Completed
Trial end date:
1998-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus
placebo in reducing or preventing the need for transfusions in anemic patients with cancer
receiving chemotherapy, and to investigate possible quality-of-life benefits associated with
the use of epoetin alfa. Epoetin alfa is a genetically engineered protein that stimulates red
blood cell production.
Phase:
Phase 3
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.